Phase 2 Newly Diagnosed Clinical Trials
30 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 30 trials
Recruiting
Phase 2
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting
Phase 1Phase 2
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 2
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
Elderly PatientsNewly Diagnosed Acute Myeloid Leukemia (AML)
Chinese PLA General Hospital120 enrolled1 locationNCT07514936
Recruiting
Phase 1Phase 2
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
Newly Diagnosed Glioblastoma
Assistance Publique - Hôpitaux de Paris35 enrolled3 locationsNCT06622434
Recruiting
Phase 2
Horizon Two: HR NDMM (MMRC-100)
High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled7 locationsNCT07053436
Recruiting
Phase 2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled11 locationsNCT06974786
Recruiting
Phase 2
18F-Fluciclovine PET/CT in Multiple Myeloma
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 2
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Newly Diagnosed Peripheral T-cell Lymphoma
Liling Zhang36 enrolled1 locationNCT05976997
Recruiting
Phase 2
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Glioblastoma MultiformeNewly Diagnosed GlioblastomaGlioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype+1 more
Northwestern University25 enrolled1 locationNCT05864534
Recruiting
Phase 2
G-CSF After Chemo-radiation in Patients With Glioblastoma
Glioblastoma (GBM)MGMT-Methylated GlioblastomaNewly Diagnosed Glioblastoma Multiforme
Massachusetts General Hospital60 enrolled1 locationNCT06649851
Recruiting
Phase 2
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
Newly Diagnosed Acute Myeloid Leukemia (AML)Intensive Chemotherapy UnfitAge ≥60
First Affiliated Hospital of Zhejiang University25 enrolled5 locationsNCT07172204
Recruiting
Phase 2
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Newly Diagnosed Glioblastoma
Duke University92 enrolled1 locationNCT06816927
Recruiting
Phase 2
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Newly DiagnosedAcute Monocytic Leukemia
The First Affiliated Hospital of Soochow University92 enrolled1 locationNCT05566054
Recruiting
Phase 2
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia, AdultNewly Diagnosed
The First Affiliated Hospital of Soochow University172 enrolled1 locationNCT06532552
Recruiting
Phase 1Phase 2
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Newly Diagnosed MGMT Unmethylated Glioblastoma
Darell Bigner50 enrolled1 locationNCT05734560
Recruiting
Phase 1Phase 2
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
LeukemiaNewly DiagnosedMyeloid+1 more
Molecular Partners AG249 enrolled9 locationsNCT05673057
Recruiting
Phase 2
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07106710
Recruiting
Phase 2
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT07106736
Recruiting
Phase 2
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
Multiple Myeloma, Newly Diagnosed
Hospital Universitario Dr. Jose E. Gonzalez10 enrolled1 locationNCT06758375
Recruiting
Phase 2Phase 3
KPD Consolidation After ASCT in NDMM Patients
Multiple Myeloma, Newly Diagnosed
Peking University People's Hospital202 enrolled3 locationsNCT06879379